These results indicate that inhibition of COX-2 by celecoxib specifically affects the tumors of PyMT/Col1a1 mice by reducing CAF populations, and by diminishing the tumor-associated collagen deposition prevalent in PyMT/Col1a1 tumors. This evidence concerns the gene PTGS2 and neoplasm.